Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Highly effective and yet non-harmful: Fumaric acid esters to fight MS

26.03.2013
Firewall for nerve cells: RUBIN covers research reports
Success made in Bochum: Treatment of relapsing-remitting multiple sclerosis

Multiple sclerosis (MS) is a disease for which no cure has yet been found. Its progression may be delayed thanks to new drugs, but the active ingredients in those drugs are either only partially effective or may lead to severe side effects.

Recent developments in the field of dermatology have given rise to hope. Researchers in Bochum have discovered that MS symptoms are considerably alleviated through the application of an active pharmaceutical ingredient on the basis of fumaric acid that has long been successfully used against psoriasis.

Patients suffered 50% fewer flare-ups and the number of active inflammatory foci was reduced by up to 90%. Researchers have now discovered in what way fumaric acid esters protect nerve cells. Their report has been published in the international edition of RUBIN, the science magazine issued by the Ruhr University Bochum.

RUBIN online

The complete article with downloadable images may be found online at
http://www.ruhr-uni-bochum.de/rubin/rubin-international-2013/beitraege/beitrag1.html

MS: Most common neurological cause of disabilities in young adults.

Multiple sclerosis is the most common neurological cause of disabilities in young adults. In Germany, it currently affects some 130,000 patients. In MS patients, the body’s own immune system attacks the nerve fibres’ “insulating layer” and destroys it. Typically, all regions of the brain and the spinal cord are affected as the disease progresses. The inflammations result in ataxia, impairment of fine motor skills, as well as concentration loss, bladder function impairment, fatigue and depressive episodes.

Fruit acid approved for use in the food industry

Since the 1990s, various drugs that delay the progression of the disease by altering the immune system have been available. They are not harmful, yet their efficacy is quite limited. Particularly serious cases are treated with chemotherapeutic agent, which, however, may have severe, even life-threatening side effects. Researchers in Bochum have now discovered that an agent long known in the field of dermatology is highly effective in the treatment of MS episodes: fumaric acid ester. Fumaric acid is a fruit acid found in numerous plants and an approved food acidulant that also occurs naturally in the human body. The active agent has been successfully utilised in psoriasis therapy.

50% fewer episodes, 90% fewer inflammation foci

The discovery happened quite by accident: the MS symptoms of patients who suffered from both MS and psoriasis were alleviated following fumaric acid ester treatment. Accordingly, several studies were carried out. Prof Dr Ralf Gold’s team of neurologists have now presented the proof of fumaric acid ester’s efficacy: it triggers protective metabolic pathways in cells. “Nerve cells are thus protected, as if by a firewall, from inflammatory agents, mainly from free radicals and nitrogen monoxide,” explains Prof Gold. A large-scale study with more than 2,400 patients revealed that fumaric acid esters reduce MS episode frequency by up to 50% and the number of inflammatory foci visible in MRI scans by up to 90%. By changing the drug formula, indigestion, a common side effect of fumaric acid ester occurring in some 400 patients treated by the dermatological drug has been considerably reduced to some 3% to 5%. “Highly efficient and yet non-harmful – a wholly new experience in MS therapy!” Prof Gold says happily.
Bibliographic record

Ralf Gold et al.: Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. In: N Engl J Med 2012; 367:1098-1107, September 20, 2012, DOI: 10.1056/NEJMoa1114287

Further information

Prof Dr med Ralf Gold, Director at the Neurology Clinic of the Ruhr University Bochum at St. Josef-Hospital, phone 0234/509-2410, ralf.gold@rub.de

Editor: Meike Drießen

Dr. Josef König | idw
Further information:
http://www.ruhr-uni-bochum.de/rubin/rubin-international-2013/beitraege/beitrag1.html

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>